| |
Synergy Research Group (SynRG) announced the establishment of a new CRO Worldwide Network alliance with Neeman Medical International (NMI), an India-based CRO. This is the second step made by SynRG in formation of the CRO Worldwide Network being able to compete with global CROs in the bids for large international multi-center clinical studies.
“India as well as Russia is one of the world’s recognized emerging clinical trials market today. Since the very beginning of the Global CRO Alliance idea we’ve been looking for experienced and reliable partner in this country, as the US, India and China are the top strategic area of international interest for Synergy Research Group”, said Nikolay Odintsov, General Director and CEO at SynRG. “The negotiation process took 5 months, we’ve discussed numerous topics and finally are proud to announce that the right partner is found, and the Alliance Agreement is signed between SynRG and Neeman”, said Odintsov.
Mr. B. Anantharaman, Managing Director of Neeman Medical International, mentioned that the company will focus on providing end to end solutions to medium and small pharma and biotech companies including monitoring and Data Management services. The company also provides site management, monitoring and data management services to top pharmaceutical companies like GSK, Novartis, MSD, Johnson & Johnson, Sanofi-Aventis and BMS. Through this alliance, both the companies should be able to leverage the advantages of conducting clinical trials in Russia and India, the emerging hubs for clinical research.
Neeman Medical International (NMI) is one of the leading Clinical Research Organization in India headquartered in New Delhi. It's been operational since 2001 with more than 70 active sites in 17 cities and access to more than 600 qualified GCP/ICH trained investigators, 25,000 beds and 6-8 million outpatients annually with a variety of illnesses. All its 60 Clinical research coordinators are medically qualified MDs (physicians) and ICH/GCP trained. NMI is ISO 9001:2000 certified for site management, monitoring and data management and has conducted over 80 clinical trials.
Igor Stefanov, SynRG’s Director for Business Development commented, “Now we're able to share resources, as a matter of fact we've already sent a proposal to one of our prospects where some Data Management services are assumed to be outsourced from Neeman. We’ll be also doing joint marketing and business development – prepare and send proposals, and conduct presentations to the existing clients and prospects, and assist each other with related language and cultural translation issues.”
“New alliance will also deliver several important benefits to sponsors, and is another step in formation of the CRO Worldwide Network providing sponsors with the global reach, and strong local experience at decent price. Our next target is to find a partner in China. We’ve recently taken part in Russian-Chinese Forum on Biotechnological and Pharmaceutical Industries, and have established a number of good promising contacts”, said Stefanov.
Dr. Ajoy Kumar, CEO of Neeman Medical International highlighted the robust operations for site management, monitoring, data management and pharmacy services. With an operations team located present in around 25 cities in India and a data centre located in New Delhi, the delivery to clients in terms of patient enrollment, clean data and reasonable cost is of utmost importance that will be further strengthened by an alliance in Russia with SynRG.
About SynRG
Synergy Research Group (SynRG™) is a Russian contract research organization, which has been successfully operating throughout Russia and the CIS member-states since 2002. SynRG™ offers a broad range of services for conducting clinical trials for Russian and foreign pharmaceutical and biotechnological companies – from regulatory affairs to pharmaco-economic surveys. The company has its own clinical depot in Moscow, with the total area of 1950 square feet. Today, Synergy Research Group is represented in Moscow, Saint-Petersburg, Novosibirsk, Yekaterinburg and Almaty. The company’s headquarters are in Moscow.
About Neeman Medical International
Neeman Medical International is a 100 percent subsidiary of Max India Limited, headquartered in New Delhi, India. It has been operational since 2001 with more than 70 active sites in 25 cities and access to more than 600 qualified GCP/ICH trained investigators, 25,000 beds and 6-8 million outpatients annually with a variety of illnesses. Out of 140 employees, 100 are Clinical Research Coordinators/Clinical Research Associates/Project managers and all of these are medically qualified MDs (physicians).
|
office[.]synrg-pharm.com 
